Horizon Pharma beats by $0.03, beats on revs; reaffirms FY16 guidance :
- Reports Q4 (Dec) earnings of $0.63 per share, excluding non-recurring items,$0.03 better than the Capital IQ Consensus of $0.60; revenues rose 135.5% year/year to $244.5 mln vs the $240.81 mln Capital IQ Consensus, driven by strong growth in each of Horizon's business units: orphan, primary care and rheumatology, as well as the addition of new medicines.
- Reaffirms FY16 rev $1.025-1.05 bln vs. $1.04 bln consensus, EBITDA $505-520 mlnvs.
Received subpoena from the U.S. Attorney's Office in Nov. requesting documents and information related to their patient assistance programs and other aspects of its marketing and commercialization activities.
No comments:
Post a Comment